| Robert William Garcia, MD | |
|
208 Nw 2nd St, Andrews, TX 79714-6308 | |
| (432) 524-1434 | |
| (432) 524-1461 |
| Full Name | Robert William Garcia |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 37 Years |
| Location | 208 Nw 2nd St, Andrews, Texas |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700872421 | NPI | - | NPPES |
| 135187603 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | H4341 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Iraan General Hospital | Iraan, TX | Hospital |
| Permian Regional Medical Center Andrews County Ho | Andrews, TX | Hospital |
| Entity Name | General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083619712 PECOS PAC ID: 9032023841 Enrollment ID: O20031117000311 |
News Archive
The AABB Interorganizational Task Force on Domestic Disasters and Acts of Terrorism has determined that the current blood supply in the United States is adequate to fill any requests received to support the present needs of Haitian hospitals, though ongoing infrastructure and transportation issues in Haiti could delay receipt of those supplies to patients.
Scientists are indicating that children in Burkina Faso who were vaccinated against group A meningococcal meningitis and septicemia between the ages of 1-4 years in 2010, could need a booster dose of the vaccine as early as this year to ensure they remain protected.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
Today's headlines include reports about how the 2015 insurance premium rates are shaping up across the country and details of consumers' experiences in trying to get their new coverage.
A Swedish population study is helping answer lingering questions about hormone therapy safety. Published online today in Menopause, the journal of The North American Menopause Society, the study shows that estrogen-only therapy carries a lower risk of blood clots than combined estrogen-progestogen therapy, but there is no significantly increased risk of clots with combination therapy when the estrogen is transdermal, and vaginal estrogen doesn't raise the risk at all.
› Verified 2 days ago
| Entity Name | Andrews County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861488694 PECOS PAC ID: 0840241030 Enrollment ID: O20050204000348 |
News Archive
The AABB Interorganizational Task Force on Domestic Disasters and Acts of Terrorism has determined that the current blood supply in the United States is adequate to fill any requests received to support the present needs of Haitian hospitals, though ongoing infrastructure and transportation issues in Haiti could delay receipt of those supplies to patients.
Scientists are indicating that children in Burkina Faso who were vaccinated against group A meningococcal meningitis and septicemia between the ages of 1-4 years in 2010, could need a booster dose of the vaccine as early as this year to ensure they remain protected.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
Today's headlines include reports about how the 2015 insurance premium rates are shaping up across the country and details of consumers' experiences in trying to get their new coverage.
A Swedish population study is helping answer lingering questions about hormone therapy safety. Published online today in Menopause, the journal of The North American Menopause Society, the study shows that estrogen-only therapy carries a lower risk of blood clots than combined estrogen-progestogen therapy, but there is no significantly increased risk of clots with combination therapy when the estrogen is transdermal, and vaginal estrogen doesn't raise the risk at all.
› Verified 2 days ago
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20050707000531 |
News Archive
The AABB Interorganizational Task Force on Domestic Disasters and Acts of Terrorism has determined that the current blood supply in the United States is adequate to fill any requests received to support the present needs of Haitian hospitals, though ongoing infrastructure and transportation issues in Haiti could delay receipt of those supplies to patients.
Scientists are indicating that children in Burkina Faso who were vaccinated against group A meningococcal meningitis and septicemia between the ages of 1-4 years in 2010, could need a booster dose of the vaccine as early as this year to ensure they remain protected.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
Today's headlines include reports about how the 2015 insurance premium rates are shaping up across the country and details of consumers' experiences in trying to get their new coverage.
A Swedish population study is helping answer lingering questions about hormone therapy safety. Published online today in Menopause, the journal of The North American Menopause Society, the study shows that estrogen-only therapy carries a lower risk of blood clots than combined estrogen-progestogen therapy, but there is no significantly increased risk of clots with combination therapy when the estrogen is transdermal, and vaginal estrogen doesn't raise the risk at all.
› Verified 2 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
The AABB Interorganizational Task Force on Domestic Disasters and Acts of Terrorism has determined that the current blood supply in the United States is adequate to fill any requests received to support the present needs of Haitian hospitals, though ongoing infrastructure and transportation issues in Haiti could delay receipt of those supplies to patients.
Scientists are indicating that children in Burkina Faso who were vaccinated against group A meningococcal meningitis and septicemia between the ages of 1-4 years in 2010, could need a booster dose of the vaccine as early as this year to ensure they remain protected.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
Today's headlines include reports about how the 2015 insurance premium rates are shaping up across the country and details of consumers' experiences in trying to get their new coverage.
A Swedish population study is helping answer lingering questions about hormone therapy safety. Published online today in Menopause, the journal of The North American Menopause Society, the study shows that estrogen-only therapy carries a lower risk of blood clots than combined estrogen-progestogen therapy, but there is no significantly increased risk of clots with combination therapy when the estrogen is transdermal, and vaginal estrogen doesn't raise the risk at all.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert William Garcia, MD 208 Nw 2nd St, Andrews, TX 79714-6308 Ph: (432) 524-1434 | Robert William Garcia, MD 208 Nw 2nd St, Andrews, TX 79714-6308 Ph: (432) 524-1434 |
News Archive
The AABB Interorganizational Task Force on Domestic Disasters and Acts of Terrorism has determined that the current blood supply in the United States is adequate to fill any requests received to support the present needs of Haitian hospitals, though ongoing infrastructure and transportation issues in Haiti could delay receipt of those supplies to patients.
Scientists are indicating that children in Burkina Faso who were vaccinated against group A meningococcal meningitis and septicemia between the ages of 1-4 years in 2010, could need a booster dose of the vaccine as early as this year to ensure they remain protected.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
Today's headlines include reports about how the 2015 insurance premium rates are shaping up across the country and details of consumers' experiences in trying to get their new coverage.
A Swedish population study is helping answer lingering questions about hormone therapy safety. Published online today in Menopause, the journal of The North American Menopause Society, the study shows that estrogen-only therapy carries a lower risk of blood clots than combined estrogen-progestogen therapy, but there is no significantly increased risk of clots with combination therapy when the estrogen is transdermal, and vaginal estrogen doesn't raise the risk at all.
› Verified 2 days ago
Dr. Luis Miguel Esparza, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 712 Hospital Dr, Andrews, TX 79714 Phone: 432-464-2450 Fax: 432-464-2566 | |
Dr. Rahul Dinesh Puri, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Hospital Dr, Andrews, TX 79714 Phone: 432-523-6624 Fax: 432-524-1147 | |
Dr. Bonnie Eugenia Muncy, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 700 Hospital Dr, Andrews, TX 79714 Phone: 432-523-6624 Fax: 432-523-7901 | |
Amanda Compton, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Hospital Dr, Andrews, TX 79714 Phone: 432-523-6624 Fax: 432-524-1129 | |
Dr. Rand E Waddingham, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Hospital Dr, Andrews, TX 79714 Phone: 432-523-6624 Fax: 432-523-7901 | |
Dr. George G Olive, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 700 Hospital Dr, Andrews, TX 79714 Phone: 432-523-6624 Fax: 432-523-7901 |